EDITAS MEDICINE, INC. (EDIT) Return on equity 2016–2025
EDITAS MEDICINE, INC. (EDIT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-586.6%FY2025 · since FY2016: -72.2% → -586.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -586.6% | -410.0 pp |
| FY2024 | -176.6% | -132.7 pp |
| FY2023 | -43.9% | +17.2 pp |
| FY2022 | -61.1% | -26.3 pp |
| FY2021 | -34.8% | -5.3 pp |
| FY2020 | -29.5% | +21.5 pp |
| FY2019 | -51.0% | -4.4 pp |
| FY2018 | -46.6% | +11.3 pp |
| FY2017 | -57.8% | +14.4 pp |
| FY2016 | -72.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More EDIT financial trends
EDIT RevenueEDIT Net incomeEDIT Net marginEDIT Gross profitEDIT Gross marginEDIT Operating incomeEDIT Operating marginEDIT Operating cash flowEDIT Free cash flowEDIT Capital expendituresEDIT Stock buybacksEDIT Dividends paidEDIT Total assetsEDIT Total liabilitiesEDIT Shareholders’ equityEDIT overview →